摘要
目的通过观察瑞舒伐他汀治疗急性冠脉综合征(ACS)患者血清D-二聚体(D-D)及同型半胱胺酸(Hcy)水平变化,探讨瑞舒伐他汀对凝血和纤溶的影响,以及检测血清D-D和Hcy的临床价值。方法选择临床确诊的ACS患者85例,在常规治疗(溶栓、阿司匹林、氯吡格雷、低分子肝素、血管紧张素转换酶抑制剂、β2-受体阻滞剂等治疗,不予任何调脂药物)基础上采用瑞舒伐他汀治疗2周,观察血清D-D(检测采用ELISA法)和Hcy(检测采用EIA法)水平变化。结果 ACS患者存在血清D-D和Hcy水平异常升高,显著高于对照组(P<0.01);瑞舒伐他汀治疗2周后,血清D-D和Hcy水平均显著降低(P<0.01),但与对照组相比仍具有显著性(P<0.01);血清D-D与Hcy呈正相关(r=0.419,P<0.01)。结论瑞舒伐他汀可显著降低ACS患者血清D-D及Hcy水平,具有改善血液凝固、纤溶系统活性亢进、降低高Hcy血症及稳定斑块的作用,动态联合检测ACS患者血清D-D及Hcy水平有利于病情观察、指导治疗及预后判定。
Objective Through the observation of rosuvastatin calcium treatment in patients with ACS serum D - dimer and Hcy level change, to discusses to the influence on the rosuvastatin calcium in ACS patients to the blood coagulation and fi- bre, and its clinical testing value. Methods Choose ACS 85 patients with normal control group, ACS in patients with conven- tional treatment adopted based on msuvastatin calcium treatment, compared with before and after the treatment serum D - dimer and Hcy level changes. Results ACS before treatment patients serum D - dimer and Hcy level was significantly higher than the control group （P 〈0. 01 ）. Rosuvastatin calcium treatment two weeks after, serum serum D - dimer and Hcy significantly below the level before treatment （P 〈0.01 ）, but still significantly higher than normal control group （P 〈0. 01 ）. Serum the d - dimer Hcy and a significant positive correlation （ r = 0. 419, P 〈 0. 01 ）. Conclusion ACS were present a high level of the D - dimer and Hcy, after rosuvastatin calcium after treatment serum d - dimer and Hcy were significantly reduced, show rosuvastatin calcium can improve blood coagulation and fibrinolysis Bystem activity and reduce the high Hcy hyperthyroidism hematic disease, as well as the role of stable plaques, dynamic testing serum D - dimer and Hcy level change can better understand condition, guid- ing treatment and prognosis.
出处
《实用心脑肺血管病杂志》
2012年第10期1612-1613,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
